查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012986

认知功能与记忆力增强药物市场：按作用机制、剂型、应用、通路和最终用户划分－2026-2032年全球市场预测

Cognitive & Memory Enhancer Drugs Market by Mechanism Of Action, Dosage Form, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年认知功能与记忆增强药物的市值为71.3亿美元，预计2026年将成长至78.4亿美元，复合年增长率为10.95%，到2032年将达到147.7亿美元。

主要市场统计数据
基准年 2025 71.3亿美元
预计年份：2026年 78.4亿美元
预测年份 2032 147.7亿美元
复合年增长率 (%) 10.95%

对目前重塑认知功能和记忆增强药物市场的疗法、监管和商业性趋势进行简明扼要的策略性概述。

在认知和记忆增强药物领域不断发展的今天，临床开发、商业化和政策制定者需要简洁明了、切实可行的执行摘要。这些执行摘要提炼了治疗分类、製剂多样性、临床应用、通路以及影响公共和公共部门决策的监管趋势等方面的横断面资讯。本文檔旨在协助企业确定研发优先顺序、优化产品组合、制定打入市场策略并增强供应链韧性。

科学进步、不断变化的法规以及数位医疗的融合，是如何重新定义认知疗法的发展路径和价值的？

认知和记忆增强疗法领域正经历着一场变革，其驱动力包括神经科学的跨学科进展、监管机构对真实世界数据（REW）的重视以及药物获取模式的改变。我们对突触可塑性和神经传导物质调节的科学理解不断加深，推动治疗假设超越单一标靶策略，催生出一系列联合治疗和仿单标示外用药策略。同时，监管机构也日益重视适应性试验设计和以患者为中心的终点指标，从而加快了进行性神经退化性疾病和神经发育障碍的疗效和安全性评估进程。

美国近期关税对认知疗法药品采购、供应链韧性和监管时限的实际影响

美国关税和贸易政策的发展对整个医药价值链的供应链规划和成本结构产生了重大影响。影响活性成分、中间体和包装材料的关税措施增加了采购的复杂性，并促使製造地进行地理多元化。对于以往依赖集中采购的公司而言，这些变化凸显了供应商选择、库存缓衝和近岸外包等策略对于维持业务永续营运和控製成本风险的重要性。

将作用机制、製剂选择、临床应用、通路和最终用户趋势与策略重点连结起来的详细细分洞察。

细分市场分析揭示了治疗药物的研发和商业化策略应如何根据作用机制、製剂、临床适应症、通路和终端用户环境进行客製化。就作用机製而言，以胆碱酯酶抑制剂（如多奈哌齐、Galantamine他敏和Rivastigmine）为重点的项目往往强调适度的症状缓解效果和已确立的安全性，从而促进渐进式创新和更广泛的适应症。另一方面，NMDA受体拮抗剂则需要谨慎的给药和监测策略，以关注其神经生理效应。精神兴奋剂的研发分为安非他命和哌甲酯类，前者优先考虑严格的滥用风险降低和长期安全性监测。吡拉西坦和Piracetam类药物通常定位于认知增强和辅助性治疗等细分领域，因此需要独特的临床试验设计和市场推广策略。

美洲、欧洲、中东、非洲和亚太地区的地理差异如何影响监管策略、临床实践和商业化顺序？

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的研发合作机会、监管方式和打入市场策略。在美洲，研究生态系统和以支付方主导的准入模式营造了一种优先考虑严谨临床证据和支付方参与的环境，有利于那些能够产生令人信服的结果数据和卫生经济学论证的项目。区域内的跨国合作支持快速进行研究者主导的试验和官民合作关係，加速临床检验。

结合科学创新、监管应对力和伙伴关係主导的商业化：一家公司建立强大的认知疗法药物组合的策略选择。

认知和记忆增强领域的企业策略体现了创新投资、产品组合多元化和策略伙伴关係之间的平衡。主要企业正透过与科技公司在数位生物标记方面建立合作关係，并寻求许可和共同开发契约以获得互补的作用机制，从而摆脱对单一分子疗法的依赖。这种多元化降低了临床和监管方面的集中风险，同时能够提供更全面的治疗方案，将药理学与数位疗法和监测平台结合。

透过协调证据产生、供应链韧性、监管灵活性和相关人员参与，采取策略性和实用性措施来加速产品采用。

产业领导企业应优先考虑整合证据策略，使早期研发与保险公司和临床医生在应用过程中优先考虑的资料类型保持一致。投资于能够捕捉功能性和患者报告结果的临床终点，有助于加强报销谈判，并推动长期应用。此外，将数位化评估工具纳入临床试验和上市后项目，可以获得更丰富的纵向数据，并创造更具吸引力的价值提案。

结合专家访谈、临床和监管证据整合以及供应链情境分析的混合调查方法，得出可操作的见解。

本分析的研究途径整合了定性专家访谈、监管文件审查、临床文献整合和供应链图谱分析，以提供多角度的检验。主要资讯来源包括对临床医生、监管专家、采购负责人和生产负责人进行的结构化访谈，以了解当前的决策者和营运限制。次要资讯来源包括同行评审的临床研究、公开的监管决策、临床试验註册资讯和企业资讯披露信息，以检验临床和战略层面的叙述。

认知疗法成功的关键决定因素是证据的整合、营运的多样化以及策略挑战的整合，强调相关人员。

总之，在科学进步、监管机构日益重视疗效指标以及供应链和政策考量的推动下，认知和记忆增强药物领域正朝着更一体化的治疗和给药模式转变。能够将针对特定机制的研发与製剂策略、循证途径和分销实际情况相结合的机构，将更有利于将临床潜力转化为永续的患者可及性。同时，积极主动的规划和跨部门合作对于应对贸易政策和区域监管差异等外部因素至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：认知功能与记忆增强药物市场－依作用机制划分

  • 胆碱酯酶抑制剂
    • 完成 pezil
    • Galantamine
    • Rivastigmine
  • NMDA拮抗剂
  • 精神兴奋剂
    • 安非他命
    • 哌甲酯
  • 拉塞图姆
    • 安尼拉塞图姆
    • Piracetam

第九章：按剂型分類的认知功能与记忆增强药物市场

  • 胶囊
  • 注射药物
  • 口服粉剂
  • 药片

第十章：认知功能与记忆增强药物市场：依应用领域划分

  • 阿兹海默症
  • 注意力不足过动症（ADHD）
  • 整体认知能力提升
  • 帕金森氏症

第十一章 认知功能与记忆增强药物市场：按分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 认知功能与记忆增强药物市场：依最终使用者划分

  • 诊所
  • 医院

第十三章 认知功能与记忆增强药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 认知功能与记忆增强药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 认知功能与记忆增强药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国认知功能与记忆增强药物市场

第十七章：中国认知功能与记忆增强药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc
  • Allergan Plc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lundbeck A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
Product Code: MRR-431418DA4906

The Cognitive & Memory Enhancer Drugs Market was valued at USD 7.13 billion in 2025 and is projected to grow to USD 7.84 billion in 2026, with a CAGR of 10.95%, reaching USD 14.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.13 billion
Estimated Year [2026] USD 7.84 billion
Forecast Year [2032] USD 14.77 billion
CAGR (%) 10.95%

A concise and strategic orientation to the therapeutic, regulatory, and commercial dynamics reshaping cognitive and memory enhancement therapeutics today

The evolving landscape of cognitive and memory enhancer drugs demands concise, actionable synthesis for leaders across clinical development, commercialization, and policy. This executive summary distills cross-cutting insights about therapeutic classes, formulation diversity, clinical applications, distribution pathways, and regulatory dynamics that shape decision-making across private and public sectors. It is written to inform R&D prioritization, portfolio optimization, market entry strategies, and supply chain resilience efforts.

Beyond therapeutic specifics, the summary highlights systemic forces such as research innovation, changing clinician and patient expectations, and geopolitical trade dynamics that intersect with drug development and access. The aim here is not to provide exhaustive data tables but to articulate the most salient patterns, risks, and opportunities. This approach helps stakeholders synthesize complex evidence into pragmatic next steps, ensuring that clinical promise can be translated into viable products and responsible deployment while maintaining regulatory compliance and patient safety.

How converging scientific advances, regulatory evolution, and digital health integration are redefining development pathways and value assessment for cognitive therapeutics

The landscape for cognitive and memory enhancement therapeutics is undergoing transformative shifts driven by convergent advances in neuroscience, regulatory emphasis on real-world evidence, and changing models for drug access. Scientific progress in understanding synaptic plasticity and neurotransmitter modulation has broadened therapeutic hypotheses beyond single-target approaches, prompting a wave of combination and repurposing strategies. Concurrently, regulators are increasingly receptive to adaptive trial designs and patient-centric endpoints, which is accelerating how efficacy and safety are assessed in progressive neurodegenerative and neurodevelopmental indications.

In parallel, payers and health systems are redefining value, prioritizing measures of functional improvement and long-term outcomes over short-term symptomatic relief. Digital health has emerged as a force multiplier, enabling remote cognitive assessment and adherence monitoring, which in turn supports decentralized clinical trials and extended post-market surveillance. As a result, sponsors must adapt by integrating translational science with pragmatic evidence generation and by forging partnerships that span technology, clinical care, and supply chain stakeholders. These shifts demand more agile development pathways and a heightened focus on demonstrable patient benefit across heterogeneous care settings.

Practical implications of recent United States tariff measures on pharmaceutical sourcing, supply chain resilience, and regulatory timing for cognitive therapeutics

United States tariffs and trade policy developments have created material considerations for supply chain planning and cost structures across the pharmaceutical value chain. Tariff actions affecting active pharmaceutical ingredients, intermediates, and packaging components increase procurement complexity and incentivize geographic diversification of manufacturing footprints. For companies that relied on concentrated sourcing, these shifts have elevated the importance of supplier qualification, inventory buffering, and nearshoring as strategies to maintain continuity and control cost exposure.

Moreover, tariffs interact with regulatory timelines and lead times for site inspections, which can compound delays in product launches or lifecycle management activities. In response, manufacturers are investing in cross-border regulatory intelligence and scenario planning to anticipate customs and compliance impacts. Payers and procurement bodies are also reassessing pricing frameworks to reflect underlying supply chain risk. Taken together, the tariff environment reinforces the need for integrated planning across procurement, regulatory affairs, and commercial teams to safeguard access and maintain competitive positioning.

Deep segmentation insights linking mechanism of action, formulation choices, clinical applications, distribution pathways, and end-user dynamics to strategic priorities

Insight into segmentation reveals how therapeutic development and commercialization strategies must be tailored to mechanism, formulation, clinical indication, distribution pathway, and end-user setting. With respect to mechanism of action, programs focusing on cholinesterase inhibitors, including donepezil, galantamine, and rivastigmine, tend to emphasize modest symptomatic benefits and established safety profiles that favor incremental innovation and label expansion, whereas NMDA antagonists require careful dosing and monitoring strategies tied to neurophysiological effects. Psychostimulant development split into amphetamine and methylphenidate approaches prioritizes rigorous abuse potential mitigation and long-term safety surveillance, while racetam derivatives like aniracetam and piracetam often position themselves within cognitive enhancement and adjunctive therapy niches, prompting distinct clinical trial designs and marketing claims.

Formulation strategy matters: the choice among capsules, injectables, oral powders, and tablets shapes patient adherence, distribution logistics, and manufacturing considerations. Indication-specific pathways vary substantially as well; therapeutic approaches for Alzheimer's disease demand robust evidence on disease modification and functional outcomes, whereas attention deficit hyperactivity disorder programs prioritize pediatric safety and sustained efficacy, general cognitive enhancement initiatives navigate ethical and regulatory scrutiny, and Parkinson's disease applications integrate motor and non-motor symptom endpoints. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies each impose different regulatory oversight, reimbursement interfaces, and patient access patterns, which in turn affect commercialization tactics. Finally, end users concentrated in clinics and hospitals emphasize institutional formularies, physician education, and hospital-level procurement processes, underscoring the need for targeted stakeholder engagement and evidence dissemination frameworks.

How geographic variation across the Americas, Europe Middle East and Africa, and Asia Pacific dictates regulatory strategy, clinical operations, and commercialization sequencing

Regional dynamics shape R&D collaboration opportunities, regulatory approaches, and market access strategies across the Americas, Europe Middle East and Africa, and Asia Pacific. In the Americas, research ecosystems and payer-driven access models create environments that prioritize rigorous clinical evidence and payer engagement, which favors programs that generate compelling outcomes data and health economic justification. Cross-border collaboration within the region supports rapid investigator-initiated studies and public-private partnerships that accelerate clinical validation.

Across Europe, the Middle East and Africa, regulatory heterogeneity and varied reimbursement frameworks necessitate tailored country-level strategies that balance centralized regulatory pathways with local evidence generation. This region also presents opportunities for multi-jurisdictional post-market surveillance and adaptive launch sequencing. The Asia Pacific region combines rapidly evolving clinical research capacity with manufacturing scale, enabling sponsorship models that leverage local trial enrollment and cost-efficient production; however, regional regulatory expectations and clinical practice patterns require careful alignment to ensure successful adoption and reimbursement. Together, these geographic considerations inform where to locate trial activity, align manufacturing, and prioritize market entry sequencing based on clinical, regulatory, and commercial fit.

Corporate strategic choices that combine scientific innovation, regulatory readiness, and partnership-led commercialization to build resilient cognitive therapeutic portfolios

Corporate strategies within the cognitive and memory enhancement space reflect a balance of innovation investment, portfolio diversification, and strategic partnerships. Leading organizations are expanding beyond single-molecule bets by cultivating collaborative agreements with technology firms for digital biomarkers, and by pursuing licensing or co-development arrangements to access complementary mechanisms of action. This diversification reduces clinical and regulatory concentration risk while enabling more comprehensive therapeutic offerings that combine pharmacology with digital therapeutics or monitoring platforms.

Operationally, companies are strengthening regulatory affairs capabilities to navigate evolving evidentiary expectations and are enhancing pharmacovigilance systems to support long-term safety monitoring. On the commercial front, competitive differentiation increasingly stems from robust provider education, real-world evidence programs that demonstrate functional benefit, and targeted access strategies for institutional buyers. Smaller firms and academic spinouts often position themselves for strategic partnership or acquisition by prioritizing clean intellectual property, clear clinical differentiation, and manufacturable formulations that can integrate into larger organizations' distribution networks.

Strategic and operational actions that align evidence generation, supply chain resilience, regulatory agility, and stakeholder engagement to accelerate product adoption

Industry leaders should prioritize integrated evidence strategies that align early-stage development with the types of data payers and clinicians value for adoption. Investment in clinical endpoints that capture functional outcomes and patient-reported measures will strengthen reimbursement discussions and support long-term uptake. In addition, embedding digital assessment tools into trials and post-market programs can produce richer longitudinal data and enable more persuasive value narratives.

From an operational perspective, companies must diversify sourcing and qualify alternate suppliers for critical ingredients to mitigate geopolitical and tariff-related disruption. Regulatory agility should be bolstered through adaptive trial designs, proactive dialogue with authorities, and readiness to deploy real-world evidence to address emerging safety or effectiveness questions. Commercial teams should engage hospital and clinic stakeholders early, tailoring messaging to institutional formulary processes and clinician practice patterns. Finally, pursuing strategic alliances with technology providers, contract manufacturers, and regional partners can reduce time-to-market and expand delivery options for patients across heterogenous healthcare environments.

A blended methodology combining expert interviews, clinical and regulatory evidence synthesis, and supply chain scenario analysis to generate actionable intelligence

The research approach underpinning this analysis integrates qualitative expert interviews, regulatory document review, clinical literature synthesis, and supply chain mapping to triangulate insights. Primary inputs included structured interviews with clinicians, regulatory specialists, procurement officers, and manufacturing leaders to capture current decision drivers and operational constraints. Secondary sources encompassed peer-reviewed clinical studies, publicly available regulatory determinations, clinical trial registries, and company disclosures to validate clinical and strategic narratives.

Analytical methods emphasized cross-validation across data streams and scenario analysis to explore the implications of regulatory shifts, tariff changes, and commercialization choices. Particular attention was paid to methodological transparency, including documentation of interview guides, data collection dates, and criteria for inclusion of regulatory and clinical materials. This blended methodology ensures that conclusions reflect both practitioner perspectives and objective documentary evidence, producing actionable insights while acknowledging areas where additional primary data would further reduce uncertainty.

Synthesis of strategic imperatives highlighting evidence integration, operational diversification, and stakeholder alignment as determinants of success in cognitive therapeutics

In conclusion, the field of cognitive and memory enhancers is moving toward more integrated therapeutic and delivery paradigms driven by scientific progress, regulatory emphasis on meaningful outcomes, and heightened supply chain and policy considerations. Organizations that align mechanism-specific development with formulation strategies, evidence pathways, and distribution realities will be better positioned to translate clinical promise into sustainable patient access. At the same time, external forces such as trade policy and regional regulatory variation require proactive planning and cross-functional coordination.

Moving forward, success will favor sponsors who invest in rigorous, patient-centered evidence, diversify operational dependencies, and engage stakeholders across clinicians, institutions, and payers early in the development cycle. By doing so, they can not only mitigate risk but also create compelling value propositions that support adoption in diverse healthcare settings. These priorities should inform actionable roadmaps for research, manufacturing, and commercialization teams seeking to make meaningful progress in therapeutic areas where clinical need and scientific opportunity converge.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cognitive & Memory Enhancer Drugs Market, by Mechanism Of Action

  • 8.1. Cholinesterase Inhibitors
    • 8.1.1. Donepezil
    • 8.1.2. Galantamine
    • 8.1.3. Rivastigmine
  • 8.2. NMDA Antagonists
  • 8.3. Psychostimulants
    • 8.3.1. Amphetamines
    • 8.3.2. Methylphenidate
  • 8.4. Racetams
    • 8.4.1. Aniracetam
    • 8.4.2. Piracetam

9. Cognitive & Memory Enhancer Drugs Market, by Dosage Form

  • 9.1. Capsules
  • 9.2. Injectable
  • 9.3. Oral Powder
  • 9.4. Tablets

10. Cognitive & Memory Enhancer Drugs Market, by Application

  • 10.1. Alzheimer's Disease
  • 10.2. Attention Deficit Hyperactivity Disorder
  • 10.3. General Cognitive Enhancement
  • 10.4. Parkinson's Disease

11. Cognitive & Memory Enhancer Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Cognitive & Memory Enhancer Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals

13. Cognitive & Memory Enhancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cognitive & Memory Enhancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cognitive & Memory Enhancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cognitive & Memory Enhancer Drugs Market

17. China Cognitive & Memory Enhancer Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc
  • 18.6. Allergan Plc
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Biogen Inc
  • 18.10. Eisai Co., Ltd
  • 18.11. Eli Lilly and Company
  • 18.12. GlaxoSmithKline plc
  • 18.13. Johnson & Johnson
  • 18.14. Lundbeck A/S
  • 18.15. Merck & Co., Inc.
  • 18.16. Novartis AG
  • 18.17. Pfizer Inc
  • 18.18. Roche Holding AG
  • 18.19. Sanofi S.A.
  • 18.20. Takeda Pharmaceutical Company Limited
  • 18.21. Teva Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GALANTAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GALANTAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ANIRACETAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ANIRACETAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ANIRACETAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PIRACETAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PIRACETAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PIRACETAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ORAL POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ORAL POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ORAL POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GENERAL COGNITIVE ENHANCEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GENERAL COGNITIVE ENHANCEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GENERAL COGNITIVE ENHANCEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 171. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 198. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)